This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Mechanism of Action DosingDosing InformationDose AdjustmentsDrug Interactions Trial Design & EfficacyTrial DesignEfficacySafety Profile & Tolerability  Support & ResourcesFrequently Asked QuestionsEducational ResourcesHCP Experience VideosNICE GuidanceEligible patient identification resources

Prescribing Information for PAXLOVID (nirmatrelvir / ritonavir) can be found here. Adverse event reporting information can be found at the bottom of the page.

Paxlovid has a Conditional Marketing Authorisation in the United Kingdom. A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.

NICE Guidance (TA878) on treatments for patients with COVID-191View the NICE Guidance (TA878) here.1*
Paxlovid is recommended by NICE as a first line treatment for adult patients at increased risk of progression to severe COVID-191

NICE has recommended treatments for patients who do not need supplemental oxygen and are at increased risk for progression to severe COVID-19, as defined by the Independent Advisory Group Report1,2

Remdesivir is also recommended as a treatment option in hospitals for adults and paediatric patients (weighing at least 40kg)6


The decision to treat and choice of treatment is based on the individual patient’s eligibility criteria, clinical circumstances and is ultimately at the discretion of the individual prescriber. Please refer to the SmPC5 before making any prescribing decisions. 

 

 

GBHigh Risk Eligible Cohorts One Page Summary

Summary of the high risk adult patients who may be eligible for COVID-19 treatment.

Click to Download
Join us! 

Set up a PfizerPro account to access further materials and resources, and receive communication about medicines and vaccines promoted by Pfizer. 

Join now
Dosing Dosing Information Guide

Learn about PAXLOVID dosing, potential drug interactions, and how to prescribe.

Download Loading
GBEducational Resources

Explore downloadable materials to further support both you and your patients. 

Explore more
How PAXLOVID WorksLearn about how PAXLOVID inhibits replication by preventing proteolysis from occurring. Find out more

Explore more videos

Watch short educational key-opinion-leader (KOL) videos from Healthcare Professionals on their experience in managing patients at risk of severe COVID-19.

HCP Experience Videos
*Links to a third-party-website (outside of Pfizer). Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. Pfizer accepts no responsibility for the content or services of the linked site.

References:
1. ©NICE [2025] TA878: Available from https://www.nice.org.uk/guidance/ta878* All rights reserved. Subject to Notice of rights. 
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication (Accessed May 2025)
2. GOV.UK. Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report. Available at: https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report-march-2023* (accessed May 2025).
3. PAXLOVID® Summary of Product Characteristics.
4. Xevudy (sotrovimab) Summary of Product Characteristics.
5. Lagevrio (molnupiravir) Summary of Product Characteristics.
6. ©NICE [2025] TA971. Available at: https://www.nice.org.uk/guidance/ta971* (Accessed: May 2025). All rights reserved. Subject to notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
PP-C1D-GBR-0643 May 2025

Adverse Events
 

Adverse Events should be reported. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2025 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-C1D-GBR-0535. January 2025
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024.

YesNo
You are now leaving PfizerPro​​​​​

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-GBR-12070. April 2025​​​​​​​
​​​​​​​
You are now leaving PfizerPro

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

PP-UNP-GBR-12107. April 2025
​​​​​​​